Abstract. Vitamin C is considered as an important anticancer therapeutic agent although this view is debatable. In this study, we introduce a physiological mechanism demonstrating how vitamin C exerts anticancer activity that induces cell cycle arrest and apoptosis. Our previous and current data reveal that p53 tumor suppressor is the prerequisite factor for stronger anticancer effects of vitamin C. In addition, vitamin C-mediated cancer cell cytotoxicity appears to be achieved at least partly through the downregulation of the p34 SEI-1 oncoprotein. Our previous study showed that p34 SEI-1 increases the survival of various types of cancer cells by inhibiting their apoptosis. Present data suggest that vitamin C treatment decreases the p34 SEI-1 expression at the protein level and therefore alleviates its anti-apoptotic activity. Of note, SIAH1, E3 ubiquitin ligase, appears to be responsible for the p34 SEI-1 polyubiquitination and its subsequent degradation, which is dependent on p53. In summary, vitamin C increases cancer cell death by inducing SIAH1-mediated polyubiquitination/degradation of the p34 oncoprotein in a p53-dependent manner.
Introduction
Vitamin C (also known as an ascorbate or ascorbic acid) is an essential micronutrient and considered to function as an anticancer drug (1, 2) . Many studies have reported the importance of vitamin C cytotoxicity. However, the use of vitamin C as an anticancer therapeutic agent and its effectiveness remain debatable (3) (4) (5) (6) . In previous reports, 0.3-20 mM of vitamin C has been used for a pharmacological concentration in various cancer cell lines (4, 7) . This range of concentration is considered to effectively induce cancer cell death in vitro and to inhibit tumor growth in vivo. This can be achieved through intravenous (i.v.) or intraperitoneal (i.p.) injection, but not through oral dosing (4, 8) . Vitamin C is thought to modify the expression levels of the proteins that are involved in many different signaling pathways, which ultimately trigger cancer cells to be more susceptible to vitamin C (9, 10) . Most importantly, vitamin C has a significant advantage because it can selectively kill cancer cells but not normal cells in pharmacological concentrations. It is a crucial characteristic to be an ideal anticancer drug (11, 12) . Considering these facts, vitamin C can be regarded as an ideal therapeutic agent. However, its action mechanism has not yet been clearly defined. We therefore have attempted to elucidate the physiological mechanism how vitamin C can act as an anticancer agent. We previously showed that vitamin C stabilizes p53 by inducing MDM2 polyubiquitination/degradation. Stabilized p53 in turn aggravates intracellular oxidative stress and consequently causes cancer cells to be more sensitive to vitamin C (13) . In this process, p53-dependent enhancement of vitamin C cytotoxicity is caused by increased ROS (reactive oxygen species) generation via a differentially regulated p53 transcriptional network (13) . In addition, we found that the p34 SEI-1 protein level was decreased in response to vitamin C treatment. p34 has been shown to have multiple biological functions in cells (14) (15) (16) (17) . In particular, p34 SEI-1 plays vital roles in cell cycle as a transcriptional co-factor and in apoptosis as an antiapoptotic oncoprotein (14, 18, 19) . We previously showed that it inhibits cancer cell death by stabilizing XIAP (X-linked inhibitor of apoptosis protein), a potent inhibitor of apoptosis and inhibiting ROS-induced cell death through suppression of ASK1 (18, 19) . Therefore, p34
SEI-1 downregulation could be one of efficient means of suppressing tumorigenesis. On the basis of these observations, we hypothesized that decreased p34 SEI-1 might be responsible for the p53-mediated vitamin C cytotoxicity in cancer cells.
Considering the facts that vitamin C induces p53 activation and p34 SEI-1 downregulation at the protein level, we initially focused on the p53 function that controls the stability of the target proteins by regulating ubiquitination and subsequent
SIAH1-induced p34
SEI-1 polyubiquitination/degradation mediates p53 preferential vitamin C cytotoxicity proteasomal degradation among the p53-mediated many other regulating systems. This process can be mediated by three different types of enzymes (E1, E2 and E3) that are required for the ubiquitination-proteasomal pathway (20) (21) (22) (23) . Among them, the expression of SIAH1, E3 ubiquitin-protein ligase, is strongly dependent on p53 (24, 25) . It is a member of the SIAH family that belong to the ring domain ubiquitin ligases (26) . SIAH1 is involved in numerous cellular processes including apoptosis, tumor suppression, cell cycle, axon guidance, transcription regulation and tumor necrosis factor signaling (27) (28) (29) (30) . In particular, SIAH1 negatively affects cancer cell survival and proliferation. Thus, deregulation of the SIAH1 expression is strongly related to cancer progression (31) (32) (33) . Accordingly, SIAH1 activation could be an important factor to block tumorigenesis (33) .
In this report, we propose that vitamin C treatment of cancer cells enhances p53 activity, which in turn induces the SIAH1-mediated polyubiquitination/degradation of the p34 SEI-1 oncoprotein and ultimately increases cancer cells cytotoxicity.
Materials and methods

Cell lines, cell culture and vitamin C preparation. HCT116
+/+ (p53 wild-type) and HCT116 -/-(p53 null-type) colon cancer cell lines were provided by Dr Bert Vogelstein (Johns Hopkins University, USA) and MCF7 was obtained from the ATCC (American Type Culture Collection, USA). Each cell line was cultured in DMEM (Dulbecco's modified Eagle's medium) medium (WelGENE, Korea) supplemented with 10% fetal bovine serum and 1% antibiotic-antimycotic (both from Gibco BRL, USA). Cells were cultured at 37˚C in a humidified atmosphere composed of 95% air and 5% CO 2 . Vitamin C was adjusted to pH 7.0 using sodium hydroxide and it was prepared immediately prior to use.
Western blotting. Western blot analysis was performed as previously described (13) . The antibodies used in this study were purchased as follows: p53 (Santa Cruz Biotechnology, sc-126, USA), phospho-p53 (Ser46) (Santa Cruz Biotechnology, sc-101764), phospho-p53 (Ser15) ( , 5'-CAGUGUGG CUGACAACUUACUGG-3') for 48-72 h. The expression level of each protein was examined by using western blot analysis.
Flow cytometric analysis.
To detect the cell cycle arrest, vitamin C treated cells were harvested and washed three times with PBS (phosphate-buffered saline). Resulting cells were added with 70% ethanol immediately and maintained at 4˚C for 1-3 h to allow cell fixation. Cells were washed with PBS and then suspended in 0.1 mg/ml propidium iodide solution at 4˚C, followed by addition of 20 µl of 10 mg/ml RNase and incubation at 37˚C for 30 min. Stained samples were analyzed by using flow cytometry (BD Biosciences, USA), in which 1x10 4 cells were recorded for each sample. Apoptosis was assessed by Annexin V-binding and propidium iodide staining. Cells were harvested and washed three times with PBS and then incubated with 1 µl of Annexin V-fluorescein isothiocynate (FITC) and 2.5 µl of propidium iodide (Enzo, cat. no. ADI-ADK-700) for 15 min on ice in the dark and analyzed on a FACSCanto machine (BD Biosciences).
Measurement of vitamin C cytotoxicity. Cell viability was determined by employing the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma-Aldrich, USA) assay as described previously (13) . HCT116 cells in 96-well plates were treated with 0.3 mM of vitamin C for 8 h. The resulting cells were then incubated with MTT for 4 h at 37˚C and the cell cytotoxicity was measured by using Perkin-Elmer Wallac 1420 Victor2™ microplate reader (Perkin-Elmer, USA). Cell death was measured by using trypan blue exclusion assay.
Colony forming assay. Cells were seeded at a density of 2x10 2 per 60 mm 3 dish and treated with 2 mM of vitamin C for 24 h after pretreatment with or without 2 mM of NAC (N-acetyl-L-cysteine) and then cultured for 17 days. Colonies were fixed with 3.7% formaldehyde and counted after staining with 0.05% crystal violet solution.
Co-immunoprecipitation (co-IP) and ubiquitination assay.
Cell lysates were prepared by lysing cells in RIPA buffer with protease inhibitors, followed by pre-clearing with protein A/G Sepharose (Santa Cruz Biotechnology, sc-2020). The precleared lysates were incubated with either anti-p34 SEI-1 (Enzo Life Sciences, cat. no. ALX-804-645) or anti-SIAH1 (Santa Cruz Biotechnology, sc-5505) antibodies for 16 h at 4˚C with continuous agitation, in which the protein A/G Sepharose was added. The resulting complex with antibody and agarose A/G bead was centrifuged at 10,000 x g for 5 min and then washed with RIPA buffer three times. The proteins were eluted from the beads by boiling in an SDS sample buffer. They were then analyzed using a western blotting with the corresponding antibodies. For the p34 SEI-1 ubiquitination experiments, HCT116
+/+ or HCT116 -/-cells were transfected with indicating plasmids. The cells were then treated with 20 µM of MG132 proteasome inhibitor (A.G. Scientific, cat. no. M-1157, USA) for 16 h and lysed with RIPA buffer containing protease inhibitors. The lysates were centrifuged to obtain cytosolic proteins. Ubiquitinated p34
SEI-1 was immunoprecipitated with antip34 SEI-1 antibody, followed by immunoblotting with anti-Ub antibody (Santa Cruz Biotechnology, sc-8017).
Results
Vitamin C cytotoxicity can be enhanced by p53. To confirm the dependence of vitamin C induced cytotoxicity on p53 (13), the effect of p53 on vitamin C induced cytotoxicity was checked after p53 wild-type HCT116 +/+ and p53 null mutanttype HCT116 -/-colon cancer cells were treated with indicated doses of vitamin C (Fig. 1A) . Cell viability was significantly decreased in HCT116 +/+ , suggesting that p53 enhances vitamin C induced cytotoxicity. Cell death of vitamin C-treated HCT116 +/+ was approximately two times higher than that of the HCT116 -/-cells (Fig. 1B) . Colony forming assay was employed to further examine the relationship between vitamin C cytotoxicity and p53. Colony formation of HCT116 +/+ cells was greatly decreased by vitamin C treatment compared to those +/+ and HCT116 -/-cells were treated with 2 mM of vitamin C for 8 h and then harvested and incubated with propidium iodide followed by flow cytometry analysis. Numbers indicate the percentage of cells. Representative result is shown from three independent experiments. (E) HCT116 cells were treated with 2 mM of vitamin C for 8 h. The cells were evaluated for quantification of apoptosis by using Annexin V/propidium iodide followed by flow cytometry analysis. Representative images are shown from three independent experiments. (F) The expression levels of the proteins responding to the vitamin C treatment were analyzed using western blotting. γ-tubulin was used as a loading control.
of control and HCT116 -/-cells (Fig. 1C) . The treatment of NAC antioxidant alleviated vitamin C-mediated decrease in colony forming of HCT116 +/+ , which is consistent with our previous results (13) . The data indicate that vitamin C kills cancer cells by enhancing ROS production in the presence of p53. Next question was how p53 can positively affect vitamin C induced cytotoxicity in cancer cells. Previous reports have shown that vitamin C affects various signaling pathways related with cell cycle and apoptosis (12, (35) (36) (37) . In our present study, vitamin C induced G2/M arrest at a higher level in HCT116 +/+ cells compared to that in HCT116 -/-cells (Fig. 1D ). Furthermore, much higher level of apoptosis was also induced in HCT116 +/+ than that of HCT116 -/-cells in response to vitamin C treatment (Fig. 1E) . These findings indicate that both cell cycle arrest and apoptosis was much more sensitive to vitamin C treatment in wild-type p53 expressing HCT116 cells. Based on these results, western blot analysis was performed to examine the changes in expression levels of genes that play vital roles in cell cycle arrest and apoptosis in vitamin C-treated HCT116 cell lines. Vitamin C treatment to HCT116 +/+ resulted in phosphorylation of p53 on serine 15 (p-p53 Ser15) and serine 46 (p-p53 Ser46) residues probably due to p38MAPK activation (Fig. 1F ). This conclusion was supported by treatment of p38 inhibitor, SB203580, in which phosphorylation levels of both p38 and p53 (Ser46) were decreased (data not shown). It is well known that the phosphorylation of p53 on the serine 15 residue leads to p53 stabilization and activation and the phosphorylation of p53 on the serine 46 residue induces apoptosis (38,39) by activating p38MAPK via phosphorylation on two residues, threonine 180 and threonine 182 (Thr180/Tyr182) (13, 40, 41) . The effect of vitamin C on cell cycle was checked by examining the expression levels of p21 and cdc25c, major cell cycle regulators. Vitamin C treatment increased and decreased p21 and cdc25c protein levels only in HCT116 +/+ cells, respectively. It suggests that vitamin C treatment induced G2/M cell cycle arrest in a p53-dependent manner. Next, we checked the altered expression levels of apoptosis relating proteins, XIAP, p34 , and caspase 9. XIAP plays as a potent inhibitor of apoptosis by inhibiting caspase 3, 7 and 9 activation and its overexpression confers resistance to tumor chemotherapy (42, 43) . Interestingly, XIAP expression is known to be negatively regulated by p53 (44). Therefore, XIAP protein level was checked to examine involvement of XIAP in vitamin C-mediated apoptosis. XIAP expression was significantly decreased in HCT116 +/+ cells but not in HCT116
-/-cells in response to vitamin C. According to our previous result, XIAP stability can be greatly increased by p34 SEI-1 (19) . Very interestingly, p34 SEI-1 protein level was decreased only in HCT116 +/+ cells but not in HCT116 -/-cells. It suggests that p53 is responsible for the downregulation of the XIAP and p34 proteins in response to the vitamin C treatment. This conclusion was confirmed by checking caspase 9 activation, one of direct targets of XIAP (45, 46) . Cleaved active form of caspase 9 was found to be increased in vitamin C-treated HCT116 +/+ but not in HCT116 -/- (Fig. 1F) . The data imply that vitamin C may initiate the apoptotic process through downregulating XIAP and p34
SEI-1 in p53 wild-type cells. Considering that p34
SEI-1 plays important roles in tumorigenesis as a vital regulator of -/-cells were treated with 2 mM of vitamin C and protein levels of SIAH1 and p34 SEI-1 were analyzed by using western blotting. γ-tubulin was used as a loading control.
cell cycle and apoptosis, we hypothesized that p34 SEI-1 might play critical roles in p53-dependent vitamin C-mediated cell cycle arrest and apoptosis.
p34 SEI-1 is involved in vitamin C-induced cell death. To determine whether p34
SEI-1 is involved in the p53-dependent vitamin C cytotoxicity, we examined whether the altered expression of p34 SEI-1 modulates the vitamin C-mediated cell death in a p53-dependent manner. In HCT116 +/+ cells, p34
overexpression alleviated cell death after vitamin C treatment compared with vector only transfected control cells ( Fig. 2A) . In contrast, p34 SEI-1 suppression in HCT116 -/-cells increased cell death compared with the control cells ( Fig. 2A) . These observations indicate that the p34 SEI-1 negatively affects vitamin C-induced cell death. The next question was how vitamin C downregulates p34 SEI-1 expression in a p53-dependent manner. Our result showed that p34 SEI-1 mRNA level was not changed upon vitamin C treatment in either HCT116 +/+ or HCT116 -/-cells (Fig. 2B) . However, p34 SEI-1 protein level was greatly decreased at 8 h after vitamin C treatment but it was not changed by addition of MG132 (Fig. 2C) . The data suggest that vitamin C downregulated p34 SEI-1 at the protein level proteasome-dependently. To identify the E3 ligase responsible for the p34 SEI-1 ubiquitination/degradation in the vitamin C treated cells, we initially focused on SIAH1 E3 ubiquitin ligase because SIAH1 expression is strongly dependent on p53 (24, 32, 34) . Our data showed that SIAH1 protein level was significantly increased in HCT116 +/+ cells, but not in HCT116 -/-cells upon treatment of vitamin C, in which inverse relationship was found between SIAH1 and p34 SEI-1 expression levels (Fig. 2D) . This result implies that the SIAH1 might be responsible for the p34 SEI-1 degradation in p53 expressing cells in response to vitamin C treatment. Our collective data support the view that p34 SEI-1 is involved in vitamin C-induced cell death in p53 wild-type cells.
Vitamin C induces polyubiquitination and degradation of p34
SEI-1 in a p53-dependent manner. In order to reconfirm the essential function of p53 in the p34 SEI-1 downregulation via the SIAH1 E3 ligase, HCT116
-/-and HCT116 +/+ cells were transfected with a p53 overexpressing vector (pcDNA3.1/p53) or a p53 silencing vector (pLKO.1/p53-shRNA), respectively, and then the SIAH1 and p34 SEI-1 expression levels were checked after the vitamin C treatment. Upon the reintroduction of the wild-type p53 into the p53-deficient HCT116 -/-, vitamin C was able to downregulate intracellular p34 SEI-1 such as the case of HCT116 +/+ cells (Fig. 3A) . On the contrary, the p53 silenced HCT116
+/+ cells exhibited the similar result to that of HCT116 -/-cells (Fig. 3A) . This result suggests that p53 is required for SIAH1 upregulation and p34
SEI-1 downregulation in response to the vitamin C. To further elucidate whether the proteasome-dependent degradation of p34 SEI-1 is dependent on p53 under vitamin C treated condition, immunoprecipitation was employed to examine whether vitamin C can induce 34 SEI-1 polyubiquitination depending on p53. As shown in Fig. 3B , the vitamin C treatment significantly induced polyubiquitination of the endogenous p34 SEI-1 in the HCT116 +/+ and p53 overexpressing HCT116
-/-cells compared with the control cells. However, this effect was not detected in the HCT116 -/-and p53 silenced HCT116 +/+ cells (Fig. 3B) . Our immunoprecipitation data also revealed that SIAH1 directly interacts with p34 SEI-1 (Fig. 3B) . Collectively, these results suggest that p53 induce the direct interaction of SIAH1 with p34 SEI-1 and subsequent p34 SEI-1 ubiquitination/degradation under the conditions of a vitamin C treatment. In addition, we performed similar experiment in a wild-type p53 expressing MCF7 breast cancer cell line. p34 SEI-1 was also polyubiquitinated and degraded by the vitamin C in a wild-type p53 expressing MCF7 cells, but not in the p53 silenced MCF7 cells (data not shown). Altogether, our results strongly suggest that p53 induces the p34 SEI-1 polyubiquitination and subsequent degradation under the conditions of vitamin C treatment. . In order to confirm the SIAH1 requirement for the p53-dependent p34 SEI-1 polyubiquitination/degradation, the effect of SIAH1 on the expression and polyubiquitination of p34 SEI-1 was analyzed in the SIAH1 suppressed HCT116 +/+ cells after the vitamin C treatment. The vitamin C treatment did not induce the downregulation and polyubiquitination of p34 in SIAH1 deficient HCT116 +/+ cells even in the presence of the wild-type p53 (Fig. 4A and B) . This result strongly suggests that SIAH1 is critically required for p53-mediated p34 SEI-1 polyubiquitination/degradation. In an extended study, p34 protein level was decreased in wild-type SIAH1 expressing HCT116 +/+ cells, but not in ligase deficient mutant-type SIAH1 C44S expressing cells (Fig. 4C) . Our data also show that p34 SEI-1 polyubiquitination was more increased in wild-type SIAH1 expressing cells compared to control and SIAH1
SIAH1 is responsible for polyubiquitination/degradation of p34
C44S
expressing HCT116 +/+ cells (Fig. 4D) . Taken together, these results strongly suggest that vitamin C-mediated p34 SEI-1 polyubiquitination/degradation is achieved in a SIAH1-dependent manner.
Discussion
We previously reported that p53 makes cancer cells more sensitive to vitamin C treatment and therefore increases its cytotoxicity (13) . According to our data, vitamin C induces the MDM2 polyubiquitination/degradation and consequently stabilizes p53 (13) . It is in turn considered to modify the expression levels of different target proteins that are involved in many other signaling pathways to render cancer cells more susceptible to vitamin C. In our present study, our collective data support the view that p53 induces SIAH1-mediated polyubiquitination/degradation of the p34 SEI-1 oncogenic protein upon vitamin C treatment. However, there are controversial studies on the dependence of SIAH1 expression on p53. For example, tumor suppressor HIPK2 stability is regulated by SIAH1-mediated polyubiquitination/degradation under stress conditions, in which SIAH1 expression level is increased by p53 (34) . On the contrary, Frew et al proposed that p53 overexpression has no effect on the expression of SIAH1 genes in a p53-null mouse erythroleukemic cell line (47) . We considered that different stimuli or different cell types may evoke these discrepant results.
It has been reported that oxidative stress inducing compounds, sodium nitroprusside or cucurbitacin B can activate p53, which inhibits the cell cycle at the G2 phase (48) (49) (50) . High dose of vitamin C also causes oxidative stress to cancer cells and functions as anticancer therapeutic agent (7, 11) . Our current data showed that pharmacological concentration of vitamin C induces cell cycle arrest at the G2 phase as well as apoptosis in p53-dependent manner. p34 SEI-1 is well-known as a positive regulator of the cell cycle (15) and SIAH1 expression is also closely related to G2 arrest (30) . These data imply that vitamin C inducible G2 arrest might be at least partly influenced by SIAH1-mediated p34 SEI-1 degradation in the presence of p53.
In conclusion, our previous and current data suggest that wild-type p53 is the prerequisite factor for stronger anticancer effects of vitamin C, in which vitamin C cytotoxicity appears to be achieved at least partly through the downregulation of the p34 SEI-1 in a SIAH1-dependent manner. Therefore, p34 can be developed as a new target protein for an efficient therapeutic agent against various cancers.
